Targeting type I. phosphatidylinositol phosphate kinase inhibits breast cancer metastasis

Most deaths from breast cancer are caused by metastasis, a complex behavior of cancer cells involving migration, invasion, survival and microenvironment manipulation. Type I. phosphatidylinositol phosphate kinase ( PIPKI gamma) regulates focal adhesion assembly and its phosphorylation at Y639 is critical for cell migration induced by EGF. However, the role of this lipid kinase in tumor metastasis remains unclear. Here we report that PIPKI. is vital for breast cancer metastasis. Y639 of PIPKI gamma can be phosphorylated by stimulation of EGF and hepatocyte growth factor ( HGF), two promoting factors for breast cancer progression. Histological analysis revealed elevated Y639 phosphorylation of PIPKI gamma in invasive ductal carcinoma lesions and suggested a positive correlation with tumor grade. Orthotopically transplanted PIPKI.-depleted breast cancer cells showed substantially reduced growth and metastasis, as well as suppressed expression of multiple genes related to cell migration and microenvironment manipulation. Re-expression of wild-type PIPKI. in PIPKI.-depleted cells restored tumor growth and metastasis, reinforcing the importance of PIPKI gamma in breast cancer progression. Y639-to-F or a kinase-dead mutant of PIPKI gamma could not recover the diminished metastasis in PIPKI gamma-depleted cancer cells, suggesting that Y639 phosphorylation and lipid kinase activity are both required for development of metastasis. Further analysis with in vitro assays indicated that depleting PIPKI gamma inhibited cell proliferation, MMP9 secretion and cell migration and invasion, lending molecular mechanisms for the eliminated cancer progression. These results suggest that PIPKI gamma, downstream of EGF and/or HGF receptor, participates in breast cancer progression from multiple aspects and deserves further studies to explore its potential as a therapeutic target.